Cas:24636-93-9 3-(4-methylpiperazin-1-yl)propanehydrazide manufacturer & supplier

Chemical Name:3-(4-methylpiperazin-1-yl)propanehydrazide

CAS.NO:24636-93-9

Synonyms:3-<4-Methyl-piperazino>-propionsaeure-hydrazid

Molecular Formula:C₈H₁₈N₄O

Molecular Weight:186.25500

HS Code:2933599090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:378.6ºC at 760 mmHg

Density:N/A

Index of Refraction:

PSA:61.60000

Exact Mass:186.14800

LogP:

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 3-&lt chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,-propionsaeure-hydrazid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-&lt Use and application,4-Methyl-piperazino&gt technical grade,usp/ep/jp grade.

Related News: ICER’s researchers used a two-year treatment horizon in their model but noted that it’s unclear how long patients are supposed to remain on these treatments. The model may not fully capture the challenges the disease presents to patients, ICER acknowledged. cis-[PtI2(isopropylamine)(butylamine] manufacturers The UK government has set out plans to make the UK the best destination in the world for researchers, making sure that it continues to attract the brightest and best from the UK and from overseas, cementing its status as a science superpower. Urea, N-[1-(2-chlorophenyl)ethyl]-N’-(1-methyl-1-phenyl-3-butenyl)- suppliers (For more on Stevanato, see The Covid Vaccine Will Require Billions Of Tiny Glass Vials—And This Italian Billionaire Family Is Making Them.) 3-(2,1,3-benzothiadiazol-5-yl)-4-(3,4-diisopropoxy-5-methoxybenzyl)-5-hydroxy-5-(1,4-benzodioxan-6-yl)-5H-furan-2-one vendor & factory ICER’s researchers used a two-year treatment horizon in their model but noted that it’s unclear how long patients are supposed to remain on these treatments. The model may not fully capture the challenges the disease presents to patients, ICER acknowledged. ,ICER’s researchers used a two-year treatment horizon in their model but noted that it’s unclear how long patients are supposed to remain on these treatments. The model may not fully capture the challenges the disease presents to patients, ICER acknowledged.